Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...
Cresco Labs rally sees stock surge 75% after analyst upgrades. Despite weak financials, optimism fuels the CRLBF jump.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback